secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001171843-24-003323
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus announces positive Phase 2a data for imdusiran + VTP-300 in chronic HBV
-------------------------------------------------------------------------------

- Imdusiran + VTP-300 achieved statistically significant (p<0.05) lower HBsAg at 24 weeks post-EOT vs placebo.
- 80% treatment arm vs 16% placebo had HBsAg <100 IU/mL; 60% vs 0% <10 IU/mL at 24 weeks post-EOT.
- 84% of treatment arm patients met NA therapy discontinuation criteria vs 53% in placebo arm.
- Treatment generally safe; no SAEs or Grade 3/4 AEs; injection-site reactions and transient ALT increases.
- Additional cohort evaluating nivolumab combination fully enrolled; preliminary data expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324003323/0001171843-24-003323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324003323/f8k_060524.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-003323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer